A new modeling study from Johns Hopkins Medicine, published in Clinical Infectious Diseases (2026, DOI: 10.1093/cid/ciag038), projects that terminating CDC funding for HIV testing could trigger an average 10% rise in new infections across 18 states, equating to 12,751 additional cases over five years. This is not an RCT or prospective observational trial but a simulation model calibrated to current testing volumes, demographic patterns, and transmission dynamics. Lead author Todd Fojo and colleagues found dramatic state-level heterogeneity: Louisiana could see nearly 30% more infections, while Washington state might experience only a 2.7% increase, driven by the proportion of diagnoses currently reliant on CDC-supported tests. Rural states with fragmented healthcare access appear especially vulnerable.

Our analysis goes further. The original MedicalXpress coverage accurately reports the topline numbers but underplays systemic context and equity dimensions. What it missed is how these cuts intersect with the Biden-era 'Ending the HIV Epidemic' (EHE) initiative, which aimed for a 90% reduction in new infections by 2030. A 2023 CDC HIV Surveillance Report (real data through 2022) already showed stalled progress in the South and Midwest, with Black and Latino men who have sex with men and rural heterosexual populations bearing disproportionate burden. Losing CDC testing infrastructure would likely widen these gaps, as community-based organizations in under-resourced areas depend heavily on federal grants.

Synthesizing this with a 2021 modeling study in the Journal of Acquired Immune Deficiency Syndromes (JAIDS) by Emory University researchers (Sullivan et al.), which estimated that every dollar cut from HIV prevention generates $7 in downstream treatment costs, reveals a clear false economy. Lifetime HIV care costs now exceed $500,000 per person (updated figures from a 2024 PharmacoEconomics analysis). The Johns Hopkins model's 12,751 extra infections therefore imply more than $6 billion in added lifetime expenditures, not counting productivity losses or secondary STI surges.

Patterns from recent history reinforce the warning. During 2010s sequestration and early COVID-19 reallocations, several jurisdictions saw testing volumes drop 20-40%, correlating with rebounds in viral suppression failures and onward transmission. Syphilis and gonorrhea rates have already climbed sharply in the same Southern states flagged by the model, signaling broader sexual-health infrastructure decay. The original coverage also glossed over potential compounding effects: reduced testing lowers PrEP initiation, weakens contact tracing, and leaves undiagnosed individuals unknowingly transmitting at higher rates.

This is not merely a budgetary line item. It reflects chronic underinvestment in public health infrastructure that leaves local health departments unable to absorb federal shocks. Without robust testing, the U.S. risks reversing 40 years of progress precisely when long-acting injectables and improved diagnostics offered a genuine path toward epidemic control. Prevention funding is not discretionary spending; it is the fiscal backstop that keeps lifetime treatment bills from overwhelming Medicaid and Ryan White programs. Policymakers ignoring these modeled warnings do so at the peril of both epidemiological and economic health.